What is Travere Therapeutics, Inc.'s Shariah compliance score?

Travere Therapeutics, Inc. (TVTX) has a Shariah compliance score of 68/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Travere Therapeutics, Inc. pass AAOIFI screening?

Travere Therapeutics, Inc. (TVTX) partially passes with caution AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (TVTX: 6.2%), (3) interest-bearing deposits below 30% (TVTX: 4.5%), and (4) prohibited income below 5% (TVTX: 4.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Travere Therapeutics, Inc. stock?

Travere Therapeutics, Inc. (TVTX) has a non-permissible income ratio of 4.64%. Muslim investors should purify this percentage of any dividends received and capital gains realized from TVTX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Travere Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Travere Therapeutics, Inc. (TVTX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about TVTX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

TVTX: Is Travere Therapeutics, Inc. Halal?

Travere Therapeutics, Inc.

NASDAQHealthcareUS

$56.59

-3.22%

Market Cap: 5.3B

Compliance Status

Doubtful

Screened on Jul 19, 2026 · AAOIFI Standard 21

Acceptable

68Score

Is Travere Therapeutics, Inc. (TVTX) halal? Doubtful. Based on AAOIFI screening, Travere Therapeutics, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 68/100 (Grade: B).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

6.2% of 30.0% limit

What this means for you

You may own TVTX, with caution

Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.

Purify 4.6% of your income from TVTX

That is about $4.60 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemming from single enzyme defects, and as an auxiliary treatment for peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin tablets, are available for managing homozygous cystinuria. In its development pipeline, Travere is advancing several therapeutic candidates. Sparsentan is currently in Phase III clinical trials, being investigated for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Also under development is TVT-058, a pioneering investigational human enzyme replacement candidate, which is undergoing Phase I/II clinical trials for classical homocystinuria. The company actively engages in strategic partnerships, holding a cooperative research and development agreement with the National Institutes of Health's National Center for Advancing Translational Sciences. It also collaborates with patient advocacy groups such as CDG Care and the Alagille Syndrome Alliance, collectively working towards identifying potential small molecule therapies for NGLY1 deficiency and Alagille syndrome.

Sector: Healthcare · Industry: Biotechnology

Why This Stock Is Doubtful

Non-compliant income is 4.6% of revenue, only 0.4 points below the 5% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 19, 2026

Compliance History

Doubtfulnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track TVTX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Travere Therapeutics, Inc. (TVTX) halal to invest in?

Travere Therapeutics, Inc. (TVTX) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.

Why did Travere Therapeutics, Inc. get a B compliance rating?

Travere Therapeutics, Inc. (TVTX) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 6.2% (limit 30%); interest-bearing deposits of 4.5% (limit 30%); prohibited income of 4.64% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Travere Therapeutics, Inc.'s Shariah verdict?

Travere Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Travere Therapeutics, Inc. re-screened for Shariah compliance?

Travere Therapeutics, Inc. (TVTX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 19, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.